Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders
By Charles B. Nemeroff, MD, PhD
Studying Non-Human Primates: A Gateway to Understanding Anxiety Disorders
By Ned H. Kalin, MD
Advancing the Treatment of Anxiety Disorders: New Findings and Novel Uses for Atypical Antipsychotics
Valproate Use in Neuropsychiatric Disorders in the Elderly
By Pierre N. Tariot, MD
Divalproex in the Treatment of Migraine
By Frederick G. Freitag, DO
The Use of Divalproex in the Treatment of Addictive Disorders
By Hugh Myrick, MD and Kathleen T. Brady, MD, PhD
Schizophrenia and Valproate
By Leslie Citrome, MD, MPH
Divalproex in the Treatment of Bipolar Disorder
By Paul E. Keck, Jr, MD, and Susan L. McElroy, MD
The Efficacy of Divalproex for Partial Epilepsies
By Michael C. Smith, MD
Divalproex and Epilepsy
By L. James Willmore, MD
Pharmacokinetics, Drug Interactions, and Tolerability of Valproate
By C. Lindsay DeVane, PharmD
Pharmacology of Valproate
By Michael J. Owens, PhD, and Charles B. Nemeroff, MD, PhD
The History of Valproate in Clinical Neuroscience
By Thomas R. Henry, MD
Efficacy and Tolerability of Controlled-Release Paroxetine
By Robert N. Golden, MD
Paroxetine Treatment of Mood and Anxiety Disorders in Children and Adolescents
By Karen Dineen Wagner, MD, PhD
Clinical Management of Perinatal Depression: Focus on Paroxetine
By D. Jeffrey Newport, MD, MSCR, MDiv, and Zachary N. Stowe, MD
Paroxetine Treatment of Mood Disorders in Women: Premenstrual Dysphoric Disorder and Hot Flashes
By Kimberly A. Yonkers, MD
Paroxetine Treatment of Depression in Late Life
By Charles F. Reynolds III, MD